Health How a lab in Sask. that focuses on animals became Canada's $23M hope for a COVID-19 vaccine
Canada's Ebola vaccine almost didn't happen, new study reveals
Dalhousie University professor Matthew Herder accessed hundreds of government documents to find out what really happened as Canadian scientists tried for years to get the pharmaceutical industry interested in their discovery of an Ebola vaccine.Dalhousie University law professor Matthew Herder used Canada's Access to Information Act to obtain hundreds of documents to track the development of the vaccine (rVSV-ZEBOV) from the first experiments at Winnipeg's National Microbiology Laboratory in the early 2000s through to the Ebola epidemic in West Africa in 2014.
In the global race to find a COVID-19 vaccine, the federal government announced Monday it is pumping $23 million into an academic research lab in Saskatchewan.
The Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan started as a modest veterinary lab in 1975. But it has evolved into a world class facility that the Trudeau government is betting can develop a vaccine to stop the pandemic.
First person to receive experimental coronavirus vaccine says she learned about the trial on Facebook and had to sign a 45-page waiver before she could receive the shot - as it's revealed participants will be paid just over $1000
Jennifer Haller, 43, of Seattle, Washington said she heard about the trial about two weeks ago, when Kaiser Permanente Washington Health Research Institute 'put out a call for volunteers.'Mom-of-two, Jennifer Haller, 43, of Seattle, Washington, told Refinery 29 that she heard about the vaccine trial about two weeks ago, when Kaiser Permanente Washington Health Research Institute 'put out a call for volunteers.
The Saskatoon lab already has a head start. It has been working on coronavirus vaccines, primarily for animals, for four decades, including successful vaccines for cattle and pigs.
Today, the vaccine centre is one of only a few high-level containment facilities in the world able to conduct research on a vaccine for COVID-19.
In a wide-ranging interview Friday, VIDO-InterVac research scientist Darryl Falzarano and associate director Paul Hodgson told CBC News that in the past, generating interest in funding research into a pan-coronavirus vaccine for humans has been a challenge.
While the focus is now on stopping COVID-19, Hodgson said finding a pan-coronavirus vaccine is their "vision statement," much like a universal flu vaccine has been a goal of scientists for decades.
When Will We Have a Coronavirus Vaccine?
Though extensive efforts are underway, the timeline is still 12 to 18 months.That investigational vaccine, called mRNA-1273, has been developed by Moderna Therapeutics, and the clinical trial is being conducted at Kaiser Permanente Washington Health Research Institute Vaccine and Treatment Evaluation Unit.
"That's something we've never been able to get funding for," said Falzarano.
But that has all changed, at least for the foreseeable future. Today, there are 160 people working at the lab — and up to 30 per cent of them are working on a coronavirus vaccine.
The Public Health Agency of Canada gave VIDO-InterVac the green light to start researching a vaccine for humans in late January. Researchers isolated the virus from a sample and have since grown the virus in a cell culture and are now testing a vaccine candidate in animals.
One of the questions Hodgson says he gets asked frequently these days is, "Why can't you do a vaccine faster?"
The answer is complicated.
Foods That Weaken Your Immune System
Want to feel better faster? The first step you need to take is avoiding these foods.
The federal government's multimillion-dollar funding announcement, part of a global push to develop a vaccine, comes in the middle of an international health crisis that has already killed more than 18,000 people worldwide. As of Tuesday, Canada had more than 2,700 COVID-19 cases, resulting in 27 deaths.
Over the past two decades there have been global outbreaks of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), both caused by coronaviruses. But when the outbreaks subsided, so did the research into a vaccine.
In 2003, VIDO-InterVac was part of the rush to develop a SARS vaccine in Canada, dubbed the SARS Accelerated Vaccine Initiative. Although promising candidates were developed in a relatively short period of time, ultimately a vaccine for SARS was never put through trials and no vaccine exists today.
"Until MERS came along [in 2012], there probably wasn't that strong of evidence that a coronavirus would be something that we should worry about, and that's going to happen again," Falzarano said.
Survivors of Coronavirus Face an Uncertain Road Back to Normal
Guidelines about when patients in recovery can safely resume some aspects of their pre-coronavirus lives vary greatly around the globe, and even within countries. Get news and analysis on politics, policy, national security and more, delivered right to your inboxAdding to the uncertainty, some guidelines differ depending on the severity and type of case. Authorities in Australia have three sets of guidelines: for people who have mild cases and recover completely at home, for people who have been hospitalized, and for health-care workers.
Hodgson said scientists are using knowledge gained from SARS and MERS. But for years prior to the current outbreak, finding a pan-coronavirus vaccine for humans wasn't a priority for governments or the big pharmaceutical companies. And when it comes to finding vaccines, the research follows the money.
Two years ago, VIDO-InterVac earned a four-year grant from the Canadian Institutes of Health Research, the federal government's funding agency. The government of Saudi Arabia also kicked in grant money. The research project? A vaccine that stops the transmission of MERS from camels to humans.
"We've been working more immediately on MERS vaccines and always moving, very slowly, looking at different ways you could start to try to sell the concept better of a pan-coronavirus vaccine," Falzarano said. "It's disappointing to me. It's something that I planned to do when I worked here and then it seemed clear that nobody was too interested in [funding] that concept."
Now, funding vaccine research has become imperative. The Trudeau government has committed $11 million to VIDO-InterVac's vaccine research and an additional $12 million to increase manufacturing capabilities for clinical trials.
According to Hodgson, Canada's capacity to manufacture a vaccine domestically is concerning.
Stop rescheduling your wedding for spring 2021 — the pandemic still won't be over
Couples hoping to reschedule their weddings for spring 2021 should wait to set a new date until there's a vaccine for the coronavirus.Engaged couples are consumed by their weddings in the weeks, months, and years leading up to them, with almost every free moment taken up by decisions about cakes, invitations, and first dance songs as the big day inches closer.
"From a national security or emergency preparedness perspective, the manufacturing capacity we have has really started to go down," Hodgson said.
VIDO-InterVac had been pushing the Canadian government to increase manufacturing capacity.
'Our ultimate goal'
Three times a week, scientists from the Saskatoon lab start their long day on an early morning conference call with the World Health Organization as they spearhead Canada's contribution to the global effort to find a vaccine.
So far, Canada is one of 10 countries participating in a research network the WHO calls Solidarity, which is studying existing drugs that could potentially treat COVID-19.
Dr. Tedros Adhanom Ghebreyesus, the WHO's director-general, told a news conference Friday that international co-operation will provide the level of data necessary to determine the most effective treatments.
As of Friday, neither the U.S. nor China were listed by the WHO as participating in the Solidarity trials.
Back at VIDO-InterVac, the team is focused squarely on developing a vaccine to protect the world.
"That's our ultimate goal," Hodgson said. "It would be fantastic if we developed a cure and made $100 million and were self-sufficient from this point forward, but our vision is protecting Canada and the world from infectious diseases."
Dr. Fauci says a second wave of COVID-19 is 'not inevitable' in the fall .
In an interview on CNN, Dr. Fauci said a second wave "could happen, but it is not inevitable." He said increased testing has made him more optimistic.Dr. Anthony Fauci was more optimistic in his prediction of a "second wave" of COVID-19 hitting by the fall during a CNN interview Wednesday morning.
COVID-19 update: Trudeau warns of potential enforcement measures
Prime Minister Justin Trudeau warned of potential COVID-19 enforcement measures as individuals continue to engage in "extremely concerning" activities.
Mar. 9, 2020 - House of Assembly Proceedings
Proceedings start: 19:21 Government Business: 1:16:06 Committee of the Whole House on Supply: Transportation & Infrastructure Renewal 1:42:45 Business ...